; and (B) in each operational environment; and (2) establish a standardized tracking system— (A) for naloxone distributed under paragraph (1); and (B) of the illegal use of fentanyl and other controlled substances in the military departments. (b) Briefing Not later than June 1, 2025, the Secretary of Defense shall submit to the Committees on Armed Services of the Senate and House of Representatives a briefing regarding naloxone and fentanyl. Such briefing shall include the following elements: (1) Progress in the implementation of regulations prescribed under subsection (a). (2) The prevalence and incidence of the illegal use of fentanyl and other controlled substances in the military departments during the five years preceding the briefing. (3) Processes of the military departments to mitigate substance abuse, particularly with regards to fentanyl. (c) Naloxone defined In this section, the term naloxone means naloxone and any other medication used to reverse opioid overdose. 707. Authority to expand the TRICARE Competitive Plans Demonstration Project (a) Authority To the extent practicable, the Secretary of Defense shall seek to expand the TRICARE Competitive Plans Demonstration Project to not fewer than five locations not later than one year after the date of the enactment of this Act. (b) TRICARE Competitive Plans Demonstration Project defined In this section, the term TRICARE Competitive Plans Demonstration Project means the project designed to test the contract acquisition strategy of providing an opportunity for local, regional, and national health plans to participate in the competition for managed care support functions under the TRICARE program, in accordance with section 705(c)(3) of the National Defense Authorization Act for Fiscal Year 2017 ( Public Law 114–328